Genentech And Ipsen Agree To Develop Sustained-Release Formulations Of Recombinant Human Growth Hormone
Genentech, Inc. and Ipsen announced the recent execution of a collaborative research and development (R&D) agreement to develop sustained-release formulations of Genentech's recombinant human growth hormone [somatropin (rDNA origin)].
This R&D collaboration is in addition to and supplements a previous agreement signed in 2002 whereby Ipsen gained exclusive rights to market NutropinAq(TM) Pen throughout Europe and the rest of the world, excluding North America and Japan. Nutropin AQ Pen® for use with the Nutropin AQ Pen® cartridge was cleared for marketing by the U.S. Food and Drug Administration in April 2002 and obtained marketing authorization under the trade name NutropinAq Pen from the European Medicines Agency in March 2004. Ipsen has already launched NutropinAq Pen in 12 European countries.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Amorfix Life Sciences' test detects scrapie prions in bllod ofg scrapie-infected sheep
Infinity and MedImmune Announce Promising Biological Activity of Anti-Hsp90 Compound in Phase I GIST Trial
